New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 20, 2014
08:03 EDTIPXL, IGIGI Laboratories completes seventh ANDA filing under joint agreement with Impax
IGI Laboratories (IG) announced it has submitted its seventh abbreviated new drug application in 2014 to the FDA. The seventh ANDA submission was in connection with an existing development, supply and marketing agreement with Impax Laboratories (IPXL). The agreement designates IGI Laboratories as the developer, manufacturer, and owner of a generic topical pharmaceutical drug product, which will be licensed, marketed and distributed in the United States by Global Pharmaceuticals, Impax's generics division. In accordance with the agreement, Impax is required to pay IGI when certain milestones are met related to the filing and approval of the associated ANDA.
News For IG;IPXL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 3, 2015
08:21 EDTIGIGI Laboratories guidance conservative, says Oppenheimer
Subscribe for More Information
March 2, 2015
18:52 EDTIGOn The Fly: After Hours Movers
Subscribe for More Information
16:09 EDTIGIGI Laboratories sees FY15 revenue at least $55M-$57M, consensus $59.4M
Subscribe for More Information
16:07 EDTIGIGI Laboratories reports Q4 EPS 9c, consensus 6c
Reports Q4 revenue $13.7M, consensus $11.88M.
February 24, 2015
07:12 EDTIPXLImpax to release guidance when Tower Holdings, Lineage acquisitions completed
Subscribe for More Information
07:12 EDTIPXLImpax reports Q4 adjusted EPS 16c, consensus 12c
Reports Q4 revenue $131.2M, consensus $125.47M. Reports Q4 Global Pharmaceuticals revenue $117.9M. The increase is due to higher sales of several key generic products as well as the impact of customer credits that were recorded in the prior year period of $19.2 million as a result of customer credits relating to certain pricing activities.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use